Original ArticleDensitometry in Glucocorticoid-Induced Osteoporosis
References (43)
- et al.
Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events
J Med
(1994) - et al.
Discordance in patient classification using T-scores
J Clin Densitom
(1999) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism)
Bull John Hopkins Hosp
(1932)- et al.
Vertebral fractures resulting from prolonged cortisone and corticotropin therapy
JAMA
(1954) - et al.
Use of oral corticosteroids and risk of fractures
J Bone Miner Res
(2000) - et al.
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
Rheumatology
(2000) - et al.
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
Arthritis Rheum
(2003) - et al.
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group
N Engl J Med
(1998) - et al.
Risedronate therapy prevents corticosteroid-induced bone loss
Arthritis Rheum
(1999) - et al.
Intermittent cyclical etidronate therapy in the prevention of corticosteroid-induced osteoporosis
N Engl J Med
(1997)
Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis
Arthritis Rheum
Guidelines on the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Prevention of glucocorticoid-induced osteoporosis: Experience in a managed care setting
Arch Intern Med
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis
Endocrinology
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone
J Clin Invest
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone
J Clin Invest
Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strength
J Bone Miner Res
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis
Ann Intern Med
Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy
Br J Rheum
The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women
Arthritis Rheum
Osteoporosis in rheumatoid arthritis: saftey of low dose corticosteroids
Ann Rheum Dis
Cited by (25)
Arthritis Accompanying Endocrine and Metabolic Disorders
2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth EditionOsteoporosis in Childhood and Adolescence
2013, Osteoporosis: Fourth EditionOsteoporosis in Childhood and Adolescence
2008, Osteoporosis, Two-Volume SetDiscriminatory Ability of Calcaneal Quantitative Ultrasound in the Assessment of Bone Status in Patients With Inflammatory Bowel Disease
2007, Ultrasound in Medicine and BiologyCitation Excerpt :QUS technique has been shown to be a good predictor of fracture risk in postmenopausal women, independent of DXA (Knapp et al. 2001). Calcaneal QUS has also been demonstrated to discriminate low bone density in patients with rheumatoid arthritis and to detect bone changes in subjects taking corticosteroids (Maricic 2004). Only a few previous studies referred QUS data in IBD patients, with controversial results.
Monitoring of Dual-Energy X-ray Absorptiometry Measurement in Clinical Practice
2006, Journal of Clinical DensitometryCitation Excerpt :Recently, efficient therapeutic options for treatment of osteoporosis have been developed, which create possibilities of effective intervention. Therefore, screening for and treatment of osteoporosis are widely practiced in postmenopausal women and in people with an increased risk of osteoporosis because of underlying diseases (e.g., chronic rheumatic diseases, especially when treated with corticosteroids) (4–6). Moreover, BMD measurement is needed to select patients for osteoporosis treatment, as there is no proof that drugs for osteoporosis (other than hormone replacement therapy [HRT]) are beneficial in women with clinical risk factors for fractures but normal BMD values.
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis
2022, British Medical Bulletin